Could a vaccine tame chronic hepatitis b?

NCT ID NCT05841095

Ongoing Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 or a placebo, and researchers will monitor side effects and immune responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ISA104 (therapeutic hepatitis B virus synthetic long peptide vaccine)
What this could lead to: If successful, ISA104 could help control chronic hepatitis B by boosting the immune system, potentially reducing the need for lifelong antiviral medication.
What could go wrong: This is an early-phase trial with only 24 participants, so results may not apply widely. The vaccine may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Erasmus MC

Rotterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.